Medical network - on March 7, as recently the 2017 edition of the medical insurance directory, surrounding the new breed of speculation finally settled. Be worth what carry is, than the 2009 version, part of the proprietary Chinese medicine is the original 1032 (including the national medicine) to 1238, increased by 206, up 19.96%, much higher than the growth of western medicine. Combination of kang CMH data shows that at present the 1238 medicare catalog proprietary Chinese medicine in the scale of five domestic terminal market for 244.4 billion yuan. Into the catalogue of 206 new proprietary Chinese medicine the expansion of space? What characteristic to proprietary Chinese medicine overall market changes will present? Continue to use the data to speak.
According to kang, according to data from the CMH 1238 medicare catalog proprietary Chinese medicine formulations (split in 2191 after drug) five terminal market scale in China in 2015 is 244.4 billion yuan, accounting for 69.29% of the overall proprietary Chinese medicine market. Is expected in 2016 related products market scale will reach 255.7 billion yuan, the growth rate of about 4.61%. And 2015 09 edition in the scale of five domestic terminal market for 235.4 billion yuan. The new 206 proprietary Chinese medicine market size is about 11.5 billion yuan in 2015, this part of the scale in 2016 is expected to reach 13.1 billion yuan, the growth rate of 13.64%, higher than the overall growth of the Chinese medicines, health care.
In the 17th edition of Chinese medicines, health care sector, 2015 years ago, ten manufacturers with 26.33% market share, market concentration higher than 23.09% of the overall proprietary Chinese medicine market. Step length in 2015 topped the drug with a 4.82% market share, guangxi wuzhou ranked second with 3.43% of the market share. Due to the use of TCM injections in recent years by more and more strict restrictions, the TCM injections as pillar factory had a big impact. To cope with the challenges, many manufacturers began to potential resources into new varieties, such as step pharmaceutical and its subsidiaries including fairy refs litres of oral liquid of arteries and veins, ideas are mixture, such as dragon born vermiculite capsule, eight products has entered the new health insurance directory, but kang edge pharmaceutical industry also has a large plant rhodiola capsule eight drugs into the directory for the first time. Predictably, these products have the potential to become a new growth point of enterprise in the future.
Note: EI in 100 as a benchmark, said category's average level of development; Above average EI > 100 said product development; EI < 100 indicates below average product development, the same below.
In the top 10 brands, occupies eight TCM injections, and reflects the current status of proprietary Chinese medicine market is given priority to with injection. 2015 years ago ten brands of the market share of 16.58%, low market concentration. Due to the TCM injections are restricted, is expected to ten brand's market share fell 2016 years ago.
This new proprietary Chinese medicine, 206, in 2015, the top ten brand accounted for 39.23% of the total scale of new drugs, the sunflower pharmaceutical children lungs heat to cough and gasp the oral liquid with a 10.11% share in the first, also belong to the children's drugs pediatric dipper tea particles with 3.2% ranked seventh, reflects the expansion and the implications for children's drugs. And the expansion of new three kinds of traditional Chinese medicine (TCM) injection into the top ten. Kidney specialist medication hai kun renal xi capsule with a 3.81% share of the fifth. After being added into the medical insurance directory, these brands and related enterprise's growth prospects.
Note: 17 version of the notice of the ginkgo biloba extract and gingko leaves were separately, 09 version notice list only ginkgo leaf, so the ginkgo biloba extract piece as a new product will be calculated.
Throughout the 17th edition of the medical insurance directory Chinese medicine sector, the size of the market to further expand, drug specialist children's drugs, increase in the number, large proprietary Chinese medicine pharmaceutical companies have more potential for growth. Given that there is still a 45 plans to negotiate the product has not yet been determined whether can enter the directory, as well as the provinces of the directory is yet to be announced, at present the new catalogue for sales of related companies not have an immediate impact. But for the selected variety, brand advantage and the status of industry enterprise, there is no doubt that the most benefit. |
